SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178670-24-000021
Filing Date
2024-05-02
Accepted
2024-05-02 08:11:36
Documents
14
Period of Report
2024-05-02
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alny-20240502.htm   iXBRL 8-K 26707
2 EX-99.1 alny2024q1earningsrelease.htm EX-99.1 261252
  Complete submission text file 0001178670-24-000021.txt   441287

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alny-20240502.xsd EX-101.SCH 1973
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alny-20240502_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alny-20240502_pre.xml EX-101.PRE 13115
17 EXTRACTED XBRL INSTANCE DOCUMENT alny-20240502_htm.xml XML 2850
Mailing Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142
Business Address 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Filer) CIK: 0001178670 (see all company filings)

IRS No.: 770602661 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36407 | Film No.: 24905453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)